Interview and Video with Emeran Mayer, MD of UCLA on the Gut-Brain-Microbiome Connection in IBS

September 30, 2016

Earlier this month, WBUR, the Boston affiliate of National Public Radio published a recent interview with Emeran Mayer, MD, Director of the University of California/Los Angeles Oppenheimer Center for Neurobiology of Stress and Resilience, a leading research center for irritable bowel syndrome and other neurologically-based chronic pain conditions. Dr. Mayer also recently published a book on the mind-gut connection and is a longtime board member of the International Foundation for Functional Gastrointestinal Disorders (IFFGD).

The gut-brain or brain-gut connection has been scientifically established for over two decades to be a major factor in IBS and other functional gastrointestinal disorders, and has recently evolved to the brain-gut-microbiome connection as a result of further research since then.

Excerpts of WBUR’s interview with Dr. Mayer are available at the link below. Also included on WBUR’s web page for this article is an embedded link for a TEDxUCLA talk Dr. Mayer gave on the subject in 2015. The TEDxUCLA video has a run time of a bit over 21 minutes.

http://www.wbur.org/commonhealth/2016/09/16/the-mind-gut-connection

Although these concepts are complex and may take some time for people with IBS and family members who do not have science backgrounds to understand, the time and effort is well worth it to know more about what IBS is, might be, and is not.


Virtus Pharmaceuticals Initiates Voluntary Recall of Some U.S. Hyoscyamine Tablets -Sept. 2016

September 19, 2016

IBS Impact has recently learned of a voluntary recall of some batches of some forms of hyoscyamine tablets distributed by Virtus Pharmaceuticals. Hyoscyamine (Levsin, Levbid and other various brand names) is an anticholernergic agent prescribed for some adults and children with IBS or related functional gastrointestinal disorders. As this is a generic medication, not all hyoscyamine comes from Virtus, but readers are advised to check.

The recall involves certain lots of sublingual tablets, oral disintegrating tablets and regular tablets in the 0.125 strength only. These lots have been distributed throughout the  United States and the commonwealth of Puerto Rico since March 2016. According to the official FDA recall report, Virtus initiated this recall because some of the tablets contain either too little or too much hyoscyamine. A small portion of the affected lots also have incorrect expiration dates. There have been a few reports of various adverse symptoms from those lots that contained an unintended overdose. While the individuals required medical treatment, none of the reported situations appeared to be life threatening, and as far as is known, have resolved. Full details on the affected lot numbers and reported symptoms are in the link above. People with medication from these lots are advised to stop taking the medication and consult a doctor, especially if they have experienced any unusual symptoms or side effects. Contact information for both Virtus and the FDA is contained within the linked page.

IBS Impact encourages affected individuals to read the above links thoroughly and bring any questions or concerns to their own health care providers.